topic

879 Post-treatment neutrophil-to-lymphocyte ratio and gMDSCs as independent prognostic factors for treatment efficacy with monoclonal antibody NEO-201 and pembrolizumab
Jamie Hur, Massimo Fantini, Kwong Y Tsang, Charalampos S Floudas, Azam Ghafoor, Sharon Mavroukakis, Anjum Zaki, Ann McCoy, Erica Redmond, Christine Feierabend, Philip Arlen, Christina Annunziata

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A979-A980; DOI: 10.1136/jitc-2023-SITC2023.0879
880 Inhibition of AXL signaling with AB801 augments anti-tumor immune responses
Jhansi Leslie, Armon Goshayeshi, Eugene Park, Ruben Flores, Gonzalo Barajas, Samantha C Schwager, Enzo Stagnaro, Angelo Kaplan, Janine Kline, Ester Fernandez-Salas, Susan L Paprcka

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A981; DOI: 10.1136/jitc-2023-SITC2023.0880
881 Knockdown of neuropilin-1 by third generation antisense oligonucleotides has strong antitumor activity that can be further increased by combination with immune checkpoint inhibitors
André Maaske, Nicole Kirchhammer, Julia Festag, Laura Fernandez Rodriguez, Melanie Buchi, Monika Schell, Stefanie Raith, Sven Michel, Richard Klar, Alfred Zippelius, Frank Jaschinski

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A982; DOI: 10.1136/jitc-2023-SITC2023.0881
882 Timing and sequencing of AR-specific vaccination combined with androgen deprivation therapy affect anti-tumor responses in murine prostate cancer models
Anusha Muralidhar, Douglas McNeel

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A983; DOI: 10.1136/jitc-2023-SITC2023.0882
883 HER2-mediated T cell killing is influenced by the inverse correlation of target vs MHC class I expression on breast cancer cell lines in vitro
Ina Rohleff, Matthias Bleisch, Kanstantsin Lashuk, Julia Schueler

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A984; DOI: 10.1136/jitc-2023-SITC2023.0883
884 Tumor-directed immunoradiotherapy enhances surveillance from the sentinel lymph node
Robert Saddawi-Konefka, Riyam Al Msari, Lauren Clubb, Shiqi Tang, Riley Jones, Farhoud Faraji, Ezra Cohen, Andrew Sharabi, J Silvio Gutkind, Joseph Califano

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A985; DOI: 10.1136/jitc-2023-SITC2023.0884
885 Characterization of the tumor microenvironment in advanced breast cancer patients treated with talazoparib followed by combination of talazoparib and avelumab
Kenichi Shimada, Filipa Lynce, Xue Geng, Edward T Richardson, Candace Mainor, Mei Wei, Julie M Collins, Paula R Pohlmann, Arielle Heeke, Kelly F Zheng, Madeline G Townsend, Lauren M Sloat, Jane Staunton, Stuart J Schnitt, Joan S Brugge, Hongkun Wang, Claudine Isaacs, Geoffrey I Shapiro, Jennifer L Guerriero

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A986; DOI: 10.1136/jitc-2023-SITC2023.0885
886 In vitro study of the effects of ceralasertib (AZD6738) on the tumor microenvironment cell populations
Luis Vence, Radhika Rayanki, Tao Deng, Mohamed Moustafa, Sonia Iyer, Marta Milo, Lydia Greenlees, Steve Arbitman, Arthur Lambert, Giulia Fabbri, Raffaello Cimbro, Gemma Jones, Douglas C Palmer, Patricia McCoon

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A987; DOI: 10.1136/jitc-2023-SITC2023.0886
887 In vivo evaluation of the role of T cell help in NK cell mediated ADCC
Jyoti Arora, Caitlin D Lemke-Miltner, George J Weiner

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A988; DOI: 10.1136/jitc-2023-SITC2023.0887
888 Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma
Ryan C Augustin, Sarah Brodeur, Aofei Li, Marion Joy, Maureen Lyons, Mary Pham, Peter C Lucas, Katelyn Smith, Cindy Sander, Brian Isett, Diwakar Davar, Yana G Najjar, Hassane Zarour, John M Kirkwood, Jason J Luke, Riyue Bao

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A989; DOI: 10.1136/jitc-2023-SITC2023.0888

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages